Skip to main content
Jack Stapleton, MD, Infectious Disease, Iowa City, IA

JackTStapletonMD

Infectious Disease • Iowa City, IA

Professor, Internal Medicine, Microbiology and Immunology, University of Iowa College of Medicine

Join to view full profile

Dr. Stapleton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Stapleton's full profile

Already have an account?

  • Office

    200 Hawkins Dr
    Iowa City, IA 52242
    Phone+1 319-356-3168
    Fax+1 319-356-4600

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Infectious Disease, 1983 - 1986
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 1980 - 1983
  • University of Kansas School of Medicine
    University of Kansas School of MedicineClass of 1980

Certifications & Licensure

  • IA State Medical License
    IA State Medical License 1986 - 2025
  • NC State Medical License
    NC State Medical License 1982 - 1999
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2022

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Semen Exosomes Promote Transcriptional Silencing of HIV-1 by Disrupting NF-kB/Sp1/Tat Circuitry  
    Jack Stapleton, MD, mBio

Press Mentions

  • ‘No One Believed That It Would Ever Come to This Place’: Fear and Hatred Clouded Efforts to Care for Iowa’s Early AIDS Patients
    ‘No One Believed That It Would Ever Come to This Place’: Fear and Hatred Clouded Efforts to Care for Iowa’s Early AIDS PatientsMay 16th, 2023
  • Modified Vaccinia Ankara Vaccine Efficacious for Smallpox Protection in Phase 3 Study
    Modified Vaccinia Ankara Vaccine Efficacious for Smallpox Protection in Phase 3 StudyNovember 14th, 2019

Grant Support

  • Characterization Of Cell GBV-C Envelope Glycoprotein InteractionsVeterans Affairs2011–2012
  • GBV-C Effects On CD4 Activation And ExpansionNational Institute Of Allergy And Infectious Diseases2009–2011
  • Research Training In Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2004–2011
  • GB Virus Type C Natural History, Epidemiology, HIV InteractionNational Institute Of Allergy And Infectious Diseases2007–2008
  • Smallpox Vaccination On Endothelial Function And Human Gene ExpressionNational Center For Research Resources2005–2006
  • GBV-C Natural History, Epidemiology, HIV InteractionNational Institute Of Allergy And Infectious Diseases2004–2006
  • Effect Of GB Virus C Infection On HIV Infection, CD4 Cell Counts And HIV RNANational Center For Research Resources2005
  • Effects Of Statins On Hepatitis C And GBV-C Viral LoadsNational Center For Research Resources2004–2005
  • Smallpox Vaccination On Endothelial FunctionNational Center For Research Resources2004
  • Informed Consent To Use Stored Human Biological MaterialsNational Center For Research Resources2004
  • Aventis Pasteur'S Smallpox Vaccine In Vaccinia-NaiveNational Center For Research Resources2004
  • ACTG A5088 Interleukin-2 And Pegylated InterferonNational Center For Research Resources2004
  • Clinical Evaluation Of Echinacea And Hypericum In HIV-1 Infected SubjectsNational Institute Of Environmental Health Sciences2002
  • Trial Of IV Wf10 (TCDO) In Patients With LATE Stage HIV DiseaseNational Center For Research Resources2000–2002
  • Treatment Rollover For PTS Formerly On ACTG 328: IL-2National Center For Research Resources2000–2002
  • ACTG 5025 Hydroxyurea And Potent Antiretroviral TherapyNational Center For Research Resources2000–2002
  • ACTG 388 Trial Of Efz Or Nfv With Lamivudine/Zdv &Indinavir In HIV InfectionNational Center For Research Resources2000–2002
  • Triple Combination Drug Therapy For HIV 1 SubjectsNational Center For Research Resources1999–2002
  • ACTG 398 Amprenavir As PART Of Dual Protease Inhibitor Regimens In HIVNational Center For Research Resources1999–2002
  • ACTG 384, Protease &Non Nucleoside Reverse Transcriptase Inhibitor For HIVNational Center For Research Resources1999–2002
  • ACTG 372--Virologic Success Of Indinavir With Nucleoside Analogs In HIVNational Center For Research Resources1998–2002
  • ACTG 368--159u89 With Indivavir Sulfate And Dmp266 In HIV SubjectsNational Center For Research Resources1998–2002
  • ACTG 343--Three Maintenance Regimens For HIV Infected SubjectsNational Center For Research Resources1998–2002
  • ACTG 328--Recombinant Human Interleukin 2 In Subjects With HIVNational Center For Research Resources1998–2002
  • Evaluation Of GB Virus C Replication And HIV InhibitionNational Institute Of Allergy And Infectious Diseases2001
  • Hcv-Alcohol Interactions-- Pathogenesis And EpidemiologyNational Institute On Alcohol Abuse And Alcoholism2000–2001
  • Effects Of Alcohol On HIV ReplicationNational Center For Research Resources1998–2000
  • Delavirdine Mesylate With Zidovudine VS ZDV Alone In HIV1 SubjectsNational Center For Research Resources1998–2000
  • Nevirapine, Lamivudine And Background Nucleoside Therapy In AIDSNational Center For Research Resources1997–2000
  • Hepatitis C Virus-Alcohol Interactions-- Pathogenesis AnNational Institute On Alcohol Abuse And Alcoholism1999
  • Delavirdine Mesylate With Didanosine VS DDI Alone In HIV1 SubjectsNational Center For Research Resources1998–1999
  • Dapsone And Atovaquone For Prophylaxis Against PCP In HIV Infected PatientsNational Center For Research Resources1998–1999
  • Asymptomatic Patients On Zidovudine Monotherapy In HIV PatientsNational Center For Research Resources1998–1999
  • ACTG 320--Indinavir With Zidovudine And Lamivudine In HIV InfectionNational Center For Research Resources1998–1999
  • Delavirdine Mesylate Treatment In Triple Combination For HIV PatientsNational Center For Research Resources1996–1999
  • Delavirdine Mesylate With Zidovudine VS ZDV Alone In HIV 1 SubjectsNational Center For Research Resources1997
  • Actg--Zidovudine Monotherapy In Asymptomatic HIV Positive AdultsNational Center For Research Resources1997
  • Actg--Indinavir With Zidovudine And Lamivudine In HIV InfectionNational Center For Research Resources1997
  • Alcohol Effects On HIV ReplicationNational Institute On Alcohol Abuse And Alcoholism1996–1997
  • Didanosine And Nevirapine In HIV Positive AdultsNational Center For Research Resources1996–1997
  • Delavirdine Mesylate With Didanosine VS DDI Alone In HIV 1 SubjectsNational Center For Research Resources1996–1997
  • Actg--Dapsone And Atovaquone For Prophylaxis Against PCP In HIVNational Center For Research Resources1996–1997
  • Valacyclovir Hydrochloride Prophylaxis For CMV Disease In HIV InfectionNational Center For Research Resources1996
  • Dilavirdine Mesylate With Zidovudine VS ZDV Alone In HIV 1 SubjectsNational Center For Research Resources1996
  • Clarithromycin VS Rifabutin VS Both To Prevent Mycobacterium Avium In HIV AdultsNational Center For Research Resources1996
  • Actg--Zidovudine Therapy In HIV Positive AdultsNational Center For Research Resources1996
  • Nucleosides As Monotherapy VS Combination In NON Hemophiliac HIV PatientsNational Center For Research Resources1993
  • Immunogenicity Of An Inactivated Hepatitis A VaccineNational Center For Research Resources1993

Dr. Jack Stapleton, Dr. Jack Stapleton, MD, Dr. J Stapleton, Dr. Jack T Stapleton